VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q42886767 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241120235901.0
008 241120nneanz||abbn n and d
035 ‎‡a (WKP)Q42886767‏
024 ‎‡a 0000-0001-7190-1592‏ ‎‡2 orcid‏
035 ‎‡a (OCoLC)Q42886767‏
100 0 ‎‡a Paul Foster‏ ‎‡9 es‏ ‎‡9 sl‏ ‎‡9 ast‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a পল ফস্টার‏ ‎‡c গবেষক‏ ‎‡9 bn‏
400 0 ‎‡a Paul Foster‏ ‎‡c researcher‏ ‎‡9 en‏
400 0 ‎‡a Paul Foster‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
400 0 ‎‡a Пол Фостер‏ ‎‡9 ru‏
670 ‎‡a Author's 17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.‏
670 ‎‡a Author's 1H NMR-MS-based heterocovariance as a drug discovery tool for fishing bioactive compounds out of a complex mixture of structural analogues‏
670 ‎‡a Author's A comparative study of the ability of calcitonin gene-related peptide and adrenomedullin(13 - 52) to modulate microvascular but not thermal hyperalgesia responses‏
670 ‎‡a Author's A new micronized formulation of 2-methoxyestradiol-bis-sulfamate‏
670 ‎‡a Author's A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer.‏
670 ‎‡a Author's A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor‏
670 ‎‡a Author's Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography‏
670 ‎‡a Author's Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment.‏
670 ‎‡a Author's BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure.‏
670 ‎‡a Author's C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression‏
670 ‎‡a Author's Chimeric microtubule disruptors‏
670 ‎‡a Author's Design, synthesis, and biological evaluation of new arylamide derivatives possessing sulfonate or sulfamate moieties as steroid sulfatase enzyme inhibitors‏
670 ‎‡a Author's Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.‏
670 ‎‡a Author's Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer.‏
670 ‎‡a Author's Endothelial cells play an essential role in the thermal hyperalgesia induced by nerve growth factor.‏
670 ‎‡a Author's Estrogen Activation by Steroid Sulfatase Increases Colorectal Cancer Proliferation via GPER.‏
670 ‎‡a Author's Estrone Sulfate Transport and Steroid Sulfatase Activity in Colorectal Cancer: Implications for Hormone Replacement Therapy‏
670 ‎‡a Author's In touch with your feminine side: how oestrogen metabolism impacts prostate cancer‏
670 ‎‡a Author's In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer‏
670 ‎‡a Author's In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy.‏
670 ‎‡a Author's In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol‏
670 ‎‡a Author's NNT is a key regulator of adrenal redox homeostasis and steroidogenesis in male mice.‏
670 ‎‡a Author's Oestrogen and colorectal cancer: mechanisms and controversies‏
670 ‎‡a Author's Recent developments of steroid sulfatase inhibitors as anti-cancer agents.‏
670 ‎‡a Author's Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers‏
670 ‎‡a Author's Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents‏
670 ‎‡a Author's STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic mice‏
670 ‎‡a Author's STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells.‏
670 ‎‡a Author's STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model‏
670 ‎‡a Author's The development of steroid sulfatase inhibitors for hormone-dependent cancer therapy‏
670 ‎‡a Author's The In Vitro and In Vivo Activity of the Microtubule Disruptor STX140 Is Mediated by Hif-1 Alpha and CAIX Expression‏
670 ‎‡a Author's The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer.‏
670 ‎‡a Author's The Regulation of Steroid Action by Sulfation and Desulfation‏
670 ‎‡a Author's The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers‏
670 ‎‡a Author's The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer‏
909 ‎‡a (orcid) 0000000171901592‏ ‎‡9 1‏
919 ‎‡a recentdevelopmentsofsteroidsulfataseinhibitorsasanticanceragents‏ ‎‡A Recent developments of steroid sulfatase inhibitors as anti-cancer agents.‏ ‎‡9 1‏
919 ‎‡a useofsteroidsulfataseinhibitorsasanoveltherapeuticstrategyagainsthormonedependentendometrialcancer‏ ‎‡A The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer‏ ‎‡9 1‏
919 ‎‡a therapeuticpotentialofaseriesoforallybioavailableantiangiogenicmicrotubuledisruptorsastherapyforhormoneindependentprostateandbreastcancers‏ ‎‡A The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers‏ ‎‡9 1‏
919 ‎‡a regulationofsteroidactionbysulfationanddesulfation‏ ‎‡A The Regulation of Steroid Action by Sulfation and Desulfation‏ ‎‡9 1‏
919 ‎‡a invivopropertiesofstx243apotentangiogenesisinhibitorinbreastcancer‏ ‎‡A The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer.‏ ‎‡9 1‏
919 ‎‡a invitroandinvivoactivityofthemicrotubuledisruptorstx140ismediatedbyhif1 Alpha andcaixexpression‏ ‎‡A The In Vitro and In Vivo Activity of the Microtubule Disruptor STX140 Is Mediated by Hif-1 Alpha and CAIX Expression‏ ‎‡9 1‏
919 ‎‡a developmentofsteroidsulfataseinhibitorsforhormonedependentcancertherapy‏ ‎‡A The development of steroid sulfatase inhibitors for hormone-dependent cancer therapy‏ ‎‡9 1‏
919 ‎‡a stx2171a17βhydroxysteroiddehydrogenasetype3inhibitorisefficaciousinvivoinanovelhormonedependentprostatecancermodel‏ ‎‡A STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model‏ ‎‡9 1‏
919 ‎‡a stx140isefficaciousinvitroandinvivointaxaneresistantbreastcarcinomacells‏ ‎‡A STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells.‏ ‎‡9 1‏
919 ‎‡a stx140butnotpaclitaxelinhibitsmammarytumourinitiationandprogressioninc31sv40ttantigentransgenicmice‏ ‎‡A STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic mice‏ ‎‡9 1‏
919 ‎‡a structureactivityrelationshipsof10017cyanosubstitutedestratrienesasanticanceragents‏ ‎‡A Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents‏ ‎‡9 1‏
919 ‎‡a steroidsulfataseinhibitorsforestrogenandandrogendependentcancers‏ ‎‡A Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers‏ ‎‡9 1‏
919 ‎‡a 17betahydroxysteroiddehydrogenasetype1andnottype12isatargetforendocrinetherapyofhormonedependentbreastcancer‏ ‎‡A 17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.‏ ‎‡9 1‏
919 ‎‡a 1hnmrmsbasedheterocovarianceasadrugdiscoverytoolforfishingbioactivecompoundsoutofacomplexmixtureofstructuralanalogues‏ ‎‡A 1H NMR-MS-based heterocovariance as a drug discovery tool for fishing bioactive compounds out of a complex mixture of structural analogues‏ ‎‡9 1‏
919 ‎‡a comparativestudyoftheabilityofcalcitoningenerelatedpeptideandadrenomedullin1352tomodulatemicrovascularbutnotthermalhyperalgesiaresponses‏ ‎‡A A comparative study of the ability of calcitonin gene-related peptide and adrenomedullin(13 - 52) to modulate microvascular but not thermal hyperalgesia responses‏ ‎‡9 1‏
919 ‎‡a newmicronizedformulationof2methoxyestradiolbissulfamate‏ ‎‡A A new micronized formulation of 2-methoxyestradiol-bis-sulfamate‏ ‎‡9 1‏
919 ‎‡a newmicronizedformulationof2methoxyestradiolbissulfamatestx140istherapeuticallypotentagainstbreastcancer‏ ‎‡A A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer.‏ ‎‡9 1‏
919 ‎‡a newtherapeuticstrategyagainsthormonedependentbreastcancerthepreclinicaldevelopmentofadualaromataseandsulfataseinhibitor‏ ‎‡A A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor‏ ‎‡9 1‏
919 ‎‡a anticancersteroidsulfataseinhibitorssynthesisofapotentfluorinated2generationagentinvitroandinvivoactivitiesmolecularmodelingandproteincrystallography‏ ‎‡A Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography‏ ‎‡9 1‏
919 ‎‡a antiinflammatoryactivityofsolubleguanylatecyclasecgmpdependentdownregulationofpselectinexpressionandleukocyterecruitment‏ ‎‡A Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment.‏ ‎‡9 1‏
919 ‎‡a bcrpexpressiondoesnotresultinresistancetostx140invivodespitetheincreasedexpressionofbcrpina2780cellsinvitroafterlongtermstx140exposure‏ ‎‡A BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure.‏ ‎‡9 1‏
919 ‎‡a 100typenatriureticpeptideinhibitsleukocyterecruitmentandplateletleukocyteinteractionsviasuppressionofpselectinexpression‏ ‎‡A C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression‏ ‎‡9 1‏
919 ‎‡a chimericmicrotubuledisruptors‏ ‎‡A Chimeric microtubule disruptors‏ ‎‡9 1‏
919 ‎‡a designsynthesisandbiologicalevaluationofnewarylamidederivativespossessingsulfonateorsulfamatemoietiesassteroidsulfataseenzymeinhibitors‏ ‎‡A Design, synthesis, and biological evaluation of new arylamide derivatives possessing sulfonate or sulfamate moieties as steroid sulfatase enzyme inhibitors‏ ‎‡9 1‏
919 ‎‡a developmentofhormonedependentprostatecancermodelsfortheevaluationofinhibitorsof17betahydroxysteroiddehydrogenasetype3‏ ‎‡A Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.‏ ‎‡9 1‏
919 ‎‡a efficacyof3potentsteroidsulfataseinhibitorspreclinicalinvestigationsfortheiruseinthetreatmentofhormonedependentbreastcancer‏ ‎‡A Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer.‏ ‎‡9 1‏
919 ‎‡a endothelialcellsplayanessentialroleinthethermalhyperalgesiainducedbynervegrowthfactor‏ ‎‡A Endothelial cells play an essential role in the thermal hyperalgesia induced by nerve growth factor.‏ ‎‡9 1‏
919 ‎‡a estrogenactivationbysteroidsulfataseincreasescolorectalcancerproliferationviagper‏ ‎‡A Estrogen Activation by Steroid Sulfatase Increases Colorectal Cancer Proliferation via GPER.‏ ‎‡9 1‏
919 ‎‡a estronesulfatetransportandsteroidsulfataseactivityincolorectalcancerimplicationsforhormonereplacementtherapy‏ ‎‡A Estrone Sulfate Transport and Steroid Sulfatase Activity in Colorectal Cancer: Implications for Hormone Replacement Therapy‏ ‎‡9 1‏
919 ‎‡a intouchwithyourfemininesidehowoestrogenmetabolismimpactsprostatecancer‏ ‎‡A In touch with your feminine side: how oestrogen metabolism impacts prostate cancer‏ ‎‡9 1‏
919 ‎‡a invivoandinvitropropertiesofstx2484anovelnonsteroidalanticancercompoundactiveintaxaneresistantbreastcancer‏ ‎‡A In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer‏ ‎‡9 1‏
919 ‎‡a invivoefficacyofstx213a2generationsteroidsulfataseinhibitorforhormonedependentbreastcancertherapy‏ ‎‡A In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy.‏ ‎‡9 1‏
919 ‎‡a invivoinhibitionofangiogenesisbysulphamoylatedderivativesof2methoxyoestradiol‏ ‎‡A In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol‏ ‎‡9 1‏
919 ‎‡a nntisakeyregulatorofadrenalredoxhomeostasisandsteroidogenesisinmalemice‏ ‎‡A NNT is a key regulator of adrenal redox homeostasis and steroidogenesis in male mice.‏ ‎‡9 1‏
919 ‎‡a oestrogenandcolorectalcancermechanismsandcontroversies‏ ‎‡A Oestrogen and colorectal cancer: mechanisms and controversies‏ ‎‡9 1‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 ISNI|0000000041267212‏
996 ‎‡2 N6I|vtls000313854‏
996 ‎‡2 ISNI|0000000067272773‏
996 ‎‡2 ISNI|0000000449552797‏
996 ‎‡2 CAOONL|ncf11476639‏
996 ‎‡2 DBC|87097990731963‏
996 ‎‡2 LC|n 86083736‏
996 ‎‡2 ISNI|0000000023701468‏
996 ‎‡2 LC|no2002020616‏
996 ‎‡2 NII|DA16751625‏
996 ‎‡2 BIBSYS|90656084‏
996 ‎‡2 RERO|A013653523‏
996 ‎‡2 NII|DA09261218‏
996 ‎‡2 PTBNP|1792529‏
996 ‎‡2 NSK|000149554‏
996 ‎‡2 NTA|343558645‏
996 ‎‡2 BNC|981060945021706706‏
996 ‎‡2 SUDOC|196148804‏
996 ‎‡2 NTA|263457516‏
996 ‎‡2 LC|no 98036330‏
996 ‎‡2 SUDOC|276115635‏
996 ‎‡2 SUDOC|059198729‏
996 ‎‡2 DNB|1037210018‏
996 ‎‡2 N6I|vtls001334158‏
996 ‎‡2 ISNI|0000000374222813‏
996 ‎‡2 NUKAT|n 2010154504‏
996 ‎‡2 LC|nb2011026290‏
996 ‎‡2 ISNI|0000000044817099‏
996 ‎‡2 J9U|987007448865405171‏
996 ‎‡2 LC|nb2012011704‏
996 ‎‡2 LC|n 50023177‏
996 ‎‡2 LC|no 96056883‏
996 ‎‡2 NUKAT|n 2013199374‏
996 ‎‡2 ISNI|0000000356613802‏
996 ‎‡2 LC|n 81007507‏
996 ‎‡2 BIBSYS|90377322‏
996 ‎‡2 NTA|300379137‏
996 ‎‡2 NKC|xx0072605‏
996 ‎‡2 LC|nb2007004807‏
996 ‎‡2 NTA|130004332‏
996 ‎‡2 DNB|1211406881‏
996 ‎‡2 NLA|000035461063‏
996 ‎‡2 LC|no2006030673‏
996 ‎‡2 SUDOC|233418954‏
996 ‎‡2 DNB|1070602876‏
996 ‎‡2 BNF|16622348‏
996 ‎‡2 LC|no2020143009‏
996 ‎‡2 BIBSYS|90400039‏
996 ‎‡2 LC|nr 95039725‏
996 ‎‡2 LC|nr2004003214‏
996 ‎‡2 LC|nb 97065059‏
996 ‎‡2 BNC|981060945020906706‏
996 ‎‡2 BIBSYS|90213889‏
996 ‎‡2 BNF|15539162‏
996 ‎‡2 ISNI|000000004194966X‏
996 ‎‡2 NTA|068294948‏
996 ‎‡2 SUDOC|03030301X‏
996 ‎‡2 LC|n 88672065‏
996 ‎‡2 LC|no2013135235‏
996 ‎‡2 SUDOC|189078251‏
996 ‎‡2 BNF|17121254‏
996 ‎‡2 ISNI|0000000081883503‏
996 ‎‡2 J9U|987007440224805171‏
996 ‎‡2 NTA|13379704X‏
996 ‎‡2 BNF|12174709‏
996 ‎‡2 LC|no2015060904‏
996 ‎‡2 PLWABN|9813276195505606‏
996 ‎‡2 RERO|A003255086‏
996 ‎‡2 J9U|987007298086505171‏
996 ‎‡2 LC|n 88158286‏
996 ‎‡2 LC|nr 98023447‏
996 ‎‡2 RERO|A020061390‏
996 ‎‡2 LC|n 95103271‏
996 ‎‡2 NUKAT|n 2012211870‏
996 ‎‡2 N6I|vtls000031860‏
996 ‎‡2 CAOONL|ncf10461429‏
996 ‎‡2 ISNI|0000000384538387‏
996 ‎‡2 NUKAT|n 2016182496‏
996 ‎‡2 NII|DA15603101‏
996 ‎‡2 RERO|A020061434‏
996 ‎‡2 DNB|138370923‏
996 ‎‡2 BNF|16173419‏
996 ‎‡2 ISNI|0000000030697495‏
996 ‎‡2 ISNI|0000000121233610‏
996 ‎‡2 BNF|14473338‏
996 ‎‡2 RERO|A003255236‏
996 ‎‡2 LC|nr2005014154‏
996 ‎‡2 LC|n 86870273‏
996 ‎‡2 BIBSYS|90121463‏
996 ‎‡2 ISNI|0000000389410542‏
996 ‎‡2 NKC|xx0002384‏
996 ‎‡2 ISNI|0000000110558954‏
996 ‎‡2 BIBSYS|6090543‏
996 ‎‡2 ISNI|0000000042504427‏
996 ‎‡2 JPG|500085490‏
996 ‎‡2 BNC|981060945022106706‏
996 ‎‡2 BIBSYS|7050457‏
996 ‎‡2 ISNI|0000000370775509‏
996 ‎‡2 J9U|987007424736105171‏
996 ‎‡2 NUKAT|n 02083163‏
996 ‎‡2 BIBSYS|4065591‏
996 ‎‡2 DNB|1117236811‏
996 ‎‡2 LC|n 82252931‏
996 ‎‡2 ISNI|0000000027175653‏
996 ‎‡2 SUDOC|095862978‏
996 ‎‡2 RERO|A017636591‏
996 ‎‡2 SUDOC|260240966‏
996 ‎‡2 J9U|987007301231605171‏
996 ‎‡2 ISNI|0000000117949560‏
996 ‎‡2 RERO|A008677645‏
996 ‎‡2 LC|nb 99101689‏
996 ‎‡2 ISNI|0000000055138649‏
996 ‎‡2 NTA|069105081‏
996 ‎‡2 BNC|981060945028206706‏
996 ‎‡2 NII|DA05331694‏
996 ‎‡2 NKC|xx0203540‏
996 ‎‡2 ISNI|0000000053337046‏
996 ‎‡2 LC|no2017150841‏
996 ‎‡2 DNB|103721028X‏
996 ‎‡2 LC|no2002062541‏
996 ‎‡2 ISNI|0000000507244347‏
996 ‎‡2 LC|no2013036997‏
996 ‎‡2 LC|n 2005073045‏
996 ‎‡2 BAV|495_160806‏
996 ‎‡2 NUKAT|n 2006002371‏
996 ‎‡2 DNB|1089849729‏
996 ‎‡2 DNB|128919205‏
996 ‎‡2 NTA|069531544‏
996 ‎‡2 SUDOC|251480119‏
996 ‎‡2 LC|nb2021007447‏
996 ‎‡2 SUDOC|078694566‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏